Exicure, Inc. (NASDAQ:XCUR – Get Rating) was the target of a significant decrease in short interest during the month of April. As of April 30th, there was short interest totalling 2,330,000 shares, a decrease of 29.2% from the April 15th total of 3,290,000 shares. Based on an average trading volume of 10,860,000 shares, the days-to-cover ratio is currently 0.2 days.
XCUR opened at $0.12 on Friday. The stock has a market cap of $15.10 million, a PE ratio of -0.17 and a beta of 1.60. Exicure has a 52 week low of $0.10 and a 52 week high of $1.98. The business’s fifty day simple moving average is $0.19 and its 200 day simple moving average is $0.32.
Exicure (NASDAQ:XCUR – Get Rating) last released its earnings results on Friday, March 25th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.02. The firm had revenue of $2.12 million during the quarter. As a group, equities research analysts predict that Exicure will post -0.15 EPS for the current year.
Separately, Zacks Investment Research cut Exicure from a “buy” rating to a “hold” rating in a research note on Thursday.
About Exicure (Get Rating)
Exicure, Inc, a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen SA to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome.
- Get a free copy of the StockNews.com research report on Exicure (XCUR)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.